Hilda Bastian

Hilda Bastian

Auto-generated profile, based on publicly available information

Hilda Bastian

Bond University

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2010 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
HBHilda Bastian
Hilda Bastian
PGPaul Glasziou
Paul Glasziou
ICIain Chalmers
Iain Chalmers
Hilda Bastian and colleagues examine the extent to which critical summaries of clinical trials can be used by health professionals and the public.

9 April 2013 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
EBElaine M. Beller
Elaine M. Beller
PGPaul P. Glasziou
Paul P. Glasziou
DADouglas G. Altman
Douglas G. Altman
SHSally Hopewell
Sally Hopewell
HBHilda Bastian
Hilda Bastian
FGfor the PRISMA for Abstracts Group
for the PRISMA for Abstracts Group
Elaine Beller and colleagues from the PRISMA for Abstracts group provide a reporting guidelines for reporting abstracts of systematic reviews in journals and at conferences.

1 April 2010 in BMJ
Verified
Journal Article
Open access
PDF file
KHKarl Horvath
Karl Horvath
KKKlaus Koch
Klaus Koch
KJKlaus Jeitler
Klaus Jeitler
EMEva Matyas
Eva Matyas
RBRalf Bender
Ralf Bender
ASAndrea Siebenhofer
Andrea Siebenhofer
Objective To summarise the benefits and harms of treatments for women with gestational diabetes mellitus. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Embase, Medline, AMED, BIOSIS, CCMed, CDMS, CDSR, CENTRAL, CINAHL, DARE, HTA, NHS EED, Heclinet, SciSearch, several publishers’ databases, and reference lists of relevant secondary literature up to October 2009. Review methods Included studies were randomised controlled trials of specific treatment for gestational diabetes compared with usual care or “intensified” compared with “less intensified” specific treatment. Results Five randomised controlled trials matched the inclusion criteria for specific versus usual treatment. All studies used a two step approach with a 50 g glucose challenge test or screening for risk factors, or both, and a subsequent 75 g or 100 g oral glucose tolerance test. Meta-analyses did not show significant differences for most single end points judged to be of direct clinical importance. In women specifically treated for gestational diabetes, shoulder dystocia was significantly less common (odds ratio 0.40, 95% confidence interval 0.21 to 0.75), and one randomised controlled trial reported a significant reduction of pre-eclampsia (2.5 v 5.5%, P=0.02). For the surrogate end point of large for gestational age infants, the odds ratio was 0.48 (0.38 to 0.62). In the 13 randomised controlled trials of different intensities of specific treatments, meta-analysis showed a significant reduction of shoulder dystocia in women with more intensive treatment (0.31, 0.14 to 0.70). Conclusions Treatment for gestational diabetes, consisting of treatment to lower blood glucose concentration alone or with special obstetric care, seems to lower the risk for some perinatal complications. Decisions regarding treatment should take into account that the evidence of benefit is derived from trials for which women were selected with a two step strategy (glucose challenge test/screening for risk factors and oral glucose tolerance test).

13 August 2010 in BMJ
Verified
Journal Article
Closed access
PGPaul Glasziou
Paul Glasziou
ICIain Chalmers
Iain Chalmers
DADouglas G Altman
Douglas G Altman
HBHilda Bastian
Hilda Bastian
IBIsabelle Boutron
Isabelle Boutron
JWJohn W Williams
John W Williams
The results of thousands of trials are never acted on because their published reports do not describe the interventions in enough detail. How can we improve the reporting?

7 October 2011 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Closed access
PDF file
MDMarion Danner
Marion Danner
JHJ. Marjan Hummel
J. Marjan Hummel
FVFabian Volz
Fabian Volz
JMJeannette G. van Manen
Jeannette G. van Manen
BWBeate Wiegard
Beate Wiegard
MIMaarten J. IJzerman
Maarten J. IJzerman
Background: Patient involvement is widely acknowledged to be a valuable component in health technology assessment (HTA) and healthcare decision making. However, quantitative approaches to ascertain patients' preferences for treatment endpoints are not yet established. The objective of this study is to introduce the analytic hierarchy process (AHP) as a preference elicitation method in HTA. Based on a systematic literature review on the use of AHP in health care in 2009, the German Institute for Quality and Efficiency in Health Care (IQWiG) initiated an AHP study related to its HTA work in 2010.Methods: The AHP study included two AHP workshops, one with twelve patients and one with seven healthcare professionals. In these workshops, both patients and professionals rated their preferences with respect to the importance of different endpoints of antidepressant treatment by a pairwise comparison of individual endpoints. These comparisons were performed and evaluated by the AHP method and relative weights were generated for each endpoint.Results: The AHP study indicates that AHP is a well-structured technique whose cognitive demands were well handled by patients and professionals. The two groups rated some of the included endpoints of antidepressant treatment differently. For both groups, however, the same six of the eleven endpoints analyzed accounted for more than 80 percent of the total weight.Conclusions: AHP can be used in HTA to give a quantitative dimension to patients' preferences for treatment endpoints. Preference elicitation could provide important information at various stages of HTA and challenge opinions on the importance of endpoints.

1 January 2013 in Journal of Continuing Education in the Health Professions
Verified
Journal Article
Closed access
FLFrance Légaré
France Légaré
NMNora Moumjid-Ferdjaoui
Nora Moumjid-Ferdjaoui
RDRenée Drolet
Renée Drolet
DSDawn Stacey
Dawn Stacey
MHMartin Härter
Martin Härter
RTRichard Thomson
Richard Thomson